The Apathy Evaluation Scale: A Comparison of Subject, Informant, and Clinician Report in Cognitively Normal Elderly and Mild Cognitive Impairment
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Apathy is a common neuropsychiatric symptom in Alzheimer's disease (AD) dementia and mild cognitive impairment (MCI). Detecting apathy accurately may facilitate earlier diagnosis of AD. The Apathy Evaluation Scale (AES) is a promising tool for measurement of apathy in prodromal and possibly preclinical AD. OBJECTIVE: To compare the three AES sub-scales - subject-reported (AES-S), informant-reported (AES-I), and clinician-reported (AES-C) - over time in individuals at risk for AD due to MCI and advanced age (cognitively normal [CN] elderly). METHODS: Mixed effects longitudinal models were used to assess predictors of score for each AES sub-scale. Cox proportional hazards models were used to assess which AES sub-scales predict progression from MCI to AD dementia. RESULTS: Fifty-seven MCI and 18 CN subjects (ages 53-86) were followed for 1.4 ± 1.2 years and 0.7 ± 0.7 years, respectively. Across the three mixed effects longitudinal models, the common findings were associations between greater apathy and greater years in study, a baseline diagnosis of MCI (compared to CN), and male gender. CN elderly self-reported greater apathy compared to that reported by informants and clinicians, while individuals with MCI under-reported their apathy compared to informants and clinicians. Of the three sub-scales, the AES-C best predicted transition from MCI to AD dementia. CONCLUSION: In a sample of CN elderly and elderly with MCI, apathy increased over time, particularly in men and those with MCI. AES-S scores may be more sensitive than AES-I and AES-C scores in CN elderly, but less reliable if subjects have MCI. Moreover, the AES-C sub-scale predicted progression from MCI to AD dementia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Clinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814 · cited 2×
“Apathy Evaluation Scale (AES) 粁 Items that were not retained in the factor analysis included: (6) You put little effort into anything; (10) Someone has to tell you what to do each day; (12) You have friends; (13) Getting together with friends is important to you.”
Self-citationAlzheimer disease in the United States (2010–2050) estimated using the 2010 census
Hebert, L. E., Weuve, J., Scherr, P. A., & Evans, D. A. (2013) · Neurology · doi:10.1212/wnl.0b013e31828726f5 · Cited by 2,642
Lyketsos, C. G., Lopez, O., Jones, B., Fitzpatrick, A. L., Breitner, J., & DeKosky, S. (2002) · JAMA · doi:10.1001/jama.288.12.1475 · Cited by 2,049 · cited 1×
“social withdrawal and loss of goal oriented behavior, interest, and motivation (24-27).”
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960 · cited 1×
“Despite significant efforts to develop such therapies, few clinical trials have shown clinically significant benefit (3-5).”
Self-citationHansson, O., Zetterberg, H., Buchhave, P., Londos, E., Blennow, K., & Minthon, L. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70355-6 · Cited by 1,700 · cited 1×
“While this represents an important step toward achieving earlier diagnosis of underlying AD pathology, many people with MCI do not progress to AD dementia, and although certain markers suggest more rapid transition to AD dementia (19-23), it is not yet possible to determine with”
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312889 · Cited by 1,668
Correlation Between Elevated Levels of Amyloid β-Peptide in the Brain and Cognitive Decline
Näslund, J. (2000) · JAMA · doi:10.1001/jama.283.12.1571 · Cited by 1,268 · cited 1×
“The detection of amyloid-く via Pittsburgh Compound B (PiB) positron emission tomography (PET) imaging, which visualizes fibrillar amyloid-く in vivo (13) can function as an early biomarker for preclinical AD; however, this marker alone may not be sufficient to predict progression to AD dementia (14).”
Dickerson, B. C., Bakkour, A., Salat, D. H., Feczko, E., Pacheco, J., Greve, D. N., Grodstein, F., Wright, C. I., Blacker, D., Rosas, H. D., et al. (2009) · Cerebral Cortex · doi:10.1093/cercor/bhn113 · Cited by 1,153
Self-citationLyketsos, C. G., Steinberg, M., Tschanz, J. T., Norton, M. C., Steffens, D. C., & Breitner, J. C. S. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.5.708 · Cited by 1,144
Jack, C. R., Lowe, V. J., Weigand, S. D., Wiste, H. J., Senjem, M. L., Knopman, D. S., Shiung, M. M., Gunter, J. L., Boeve, B. F., Kemp, B. J., et al. (2009) · Brain · doi:10.1093/brain/awp062 · Cited by 1,099
Jack, C. R., Lowe, V. J., Senjem, M. L., Weigand, S. D., Kemp, B. J., Shiung, M. M., Knopman, D. S., Boeve, B. F., Klunk, W. E., Mathis, C. A., et al. (2008) · Brain · doi:10.1093/brain/awm336 · Cited by 958 · cited 1×
“While this represents an important step toward achieving earlier diagnosis of underlying AD pathology, many people with MCI do not progress to AD dementia, and although certain markers suggest more rapid transition to AD dementia (19-23), it is not yet possible to determine with”
Outcome over seven years of healthy adults with and without subjective cognitive impairment
Reisberg, B., Shulman, M. B., Torossian, C., Leng, L., & Zhu, W. (2010) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2009.10.002 · Cited by 568
Testing the Right Target and Right Drug at the Right Stage
Sperling, R. A., Jack, C. R., & Aisen, P. S. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002609 · Cited by 550
Self-citationNeuroanatomical correlates of behavioural disorders in dementia
Rosen, H. J., Allison, S. C., Schauer, G. F., Gorno-Tempini, M. L., Weiner, M. W., & Miller, B. L. (2005) · Brain · doi:10.1093/brain/awh628 · Cited by 497
Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI
Jack, C. R., Shiung, M. M., Weigand, S. D., O’Brien, P. C., Gunter, J. L., Boeve, B. F., Knopman, D. S., Smith, G. E., Ivnik, R. J., Tangalos, E. G., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000180958.22678.91 · Cited by 492
Subjective cognitive complaints and amyloid burden in cognitively normal older individuals
Amariglio, R. E., Becker, J. A., Carmasin, J., Wadsworth, L. P., Lorius, N., Sullivan, C., Maye, J. E., Gidicsin, C., Pepin, L. C., Sperling, R. A., et al. (2012) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2012.08.011 · Cited by 472 · cited 1×
“Further strengthening the importance of self and informant-reported cognitive concerns for AD are studies of CN elderly demonstrating associations of such cognitive concerns with underlying brain atrophy similar to that of MCI (82, 83) and elevated cortical amyloid burden (84).”
Self-citationConversion from subtypes of mild cognitive impairment to Alzheimer dementia
Fischer, P., Jungwirth, S., Zehetmayer, S., Weissgram, S., Hoenigschnabl, S., Gelpi, E., Krampla, W., & Tragl, K. H. (2007) · Neurology · doi:10.1212/01.wnl.0000252358.03285.9d · Cited by 471
Neuroanatomical correlates of neuropsychiatric symptoms in Alzheimer's disease
Bruen, P. D., McGeown, W. J., Shanks, M. F., & Venneri, A. (2008) · Brain · doi:10.1093/brain/awn151 · Cited by 374
Relationship between atrophy and β‐amyloid deposition in Alzheimer disease
Chételat, G., Villemagne, V. L., Bourgeat, P., Pike, K. E., Jones, G., Ames, D., Ellis, K. A., Szoeke, C., Martins, R. N., O'Keefe, G. J., et al. (2010) · Annals of Neurology · doi:10.1002/ana.21955 · Cited by 373 · cited 1×
“In general, cortical thinning has been detected in CN elderly individuals with greater amyloid burden seen on PiB PET (9, 37) and apathy has been associated with increased cortical amyloid burden in MCI (38).”
Visser, P. J., Scheltens, P., Verhey, F. R. J., Schmand, B., Launer, L. J., Jolles, J., & Jonker, C. (1999) · Journal of Neurology · doi:10.1007/s004150050387 · Cited by 319 · cited 1×
“While this represents an important step toward achieving earlier diagnosis of underlying AD pathology, many people with MCI do not progress to AD dementia, and although certain markers suggest more rapid transition to AD dementia (19-23), it is not yet possible to determine with”
Regional rates of neocortical atrophy from normal aging to early Alzheimer disease
McDonald, C. R., McEvoy, L. K., Gharapetian, L., Fennema-Notestine, C., Hagler, D. J., Holland, D., Koyama, A., Brewer, J. B., & Dale, A. M. (2009) · Neurology · doi:10.1212/wnl.0b013e3181b16431 · Cited by 299
A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease
Salloway, S., Sperling, R., Keren, R., Porsteinsson, A. P., van Dyck, C. H., Tariot, P. N., Gilman, S., Arnold, D., Abushakra, S., Hernandez, C., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e3182309fa5 · Cited by 258 · cited 2×
“Despite significant efforts to develop such therapies, few clinical trials have shown clinically significant benefit (3-5).”
Tschanz, J. T., Corcoran, C. D., Schwartz, S., Treiber, K., Green, R. C., Norton, M. C., Mielke, M. M., Piercy, K., Steinberg, M., Rabins, P. V., et al. (2011) · The American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e3181faec23 · Cited by 244
Structural correlates of apathy in Alzheimer's disease
Apostolova, L. G., Akopyan, G. G., Partiali, N., Steiner, C. A., Dutton, R. A., Hayashi, K. M., Dinov, I. D., Toga, A. W., Cummings, J. L., & Thompson, P. M. (2007) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000103914 · Cited by 190 · cited 5×
“cingulate and left medial frontal cortex (supplementary motor area) (34), Bruen et al.”
InfluentialBrain perfusion correlates of the apathy inventory dimensions of Alzheimer's disease
Benoit, M., Clairet, S., Koulibaly, P. M., Darcourt, J., & Robert, P. H. (2004) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1163 · Cited by 147 · cited 2×
“This is supported by studies showing apathy to correlate with regionally specific cortical changes in AD dementia, including microstructural alterations in white matter anisotropy of the left anterior cingulate cortex (57), reduced metabolism and perfusion of the anterior cingulate cortex (42, 58-61) and the orbitofro…”
Subjective cognitive decline: self and informant comparisons
Caselli, R. J., Chen, K., Locke, D. E. C., Lee, W., Roontiva, A., Bandy, D., Fleisher, A. S., & Reiman, E. M. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.01.003 · Cited by 145 · cited 11×
“colleagues demonstrated that both subject and informant-reported cognitive concerns predict incidence of MCI, and also found subject-reported cognitive concerns to precede informant-reported decline in individuals who developed MCI (77).”
InfluentialA SPECT study of apathy in Alzheimer's disease
Lanctôt, K. L., Moosa, S., Herrmann, N., Leibovitch, F. S., Rothenburg, L., Cotter, A., & Black, S. E. (2007) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000103633 · Cited by 126
Antiamyloid Therapy for Alzheimer's Disease — Are We on the Right Road?
Karran, E., & Hardy, J. (2014) · New England Journal of Medicine · doi:10.1056/nejme1313943 · Cited by 126 · cited 1×
“Despite ongoing and completed AD clinical trials employing multiple classes of drugs in recent years, most potentially disease-modifying therapies, especially amyloid-modifying therapies, have failed to show clinical benefit (64).”
Donovan, N. J., Wadsworth, L. P., Lorius, N., Locascio, J. J., Rentz, D. M., Johnson, K. A., Sperling, R. A., & Marshall, G. A. (2014) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2013.03.006 · Cited by 106
Self-citationRobert, P. H., Darcourt, G., Koulibaly, M. P., Clairet, S., Benoit, M., Garcia, R., Dechaux, O., & Darcourt, J. (2006) · European Journal of Neurology · doi:10.1111/j.1468-1331.2006.01088.x · Cited by 98
Neuropsychiatric Profiles in Dementia
Johnson, D. K., Watts, A. S., Chapin, B. A., Anderson, R., & Burns, J. M. (2011) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e31820d89b6 · Cited by 82
Microstructural alteration of the anterior cingulum is associated with apathy in Alzheimer disease
Kim, J. W., Lee, D. Y., Choo, I. H., Seo, E. H., Kim, S. G., Park, S. Y., & Woo, J. I. (2011) · The American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e31820dcc73 · Cited by 79
Joshi, D., Van Schoor, N. M., De Ronde, W., Schaap, L. A., Comijs, H. C., Beekman, A. T. F., & Lips, P. (2010) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2009.03641.x · Cited by 78 · cited 1×
“One such possibility is decreasing testosterone with age, which has been associated with depressive symptoms in older men (89) and apathy in the context of Parkinson’s disease (90).”
Neuropsychiatric correlates of cerebrospinal fluid biomarkers in Alzheimer's disease
Skogseth, R., Mulugeta, E., Ballard, C., Rongve, A., Nore, S., Alves, G., & Aarsland, D. (2008) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000137671 · Cited by 71 · cited 1×
“Apathy has also been associated with greater neurofibrillary tangle burden of the anterior cingulate cortex (99) in moderate to severe AD dementia and increased cerebrospinal fluid total tau and phospho-tau in mild AD dementia (100).”
Apathy: prevalence, associated factors, and prognostic value among frail, older inpatients
Hölttä, E. H., Laakkonen, M.-L., Laurila, J. V., Strandberg, T. E., Tilvis, R. S., & Pitkälä, K. H. (2012) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2012.04.005 · Cited by 64
Guercio, B. J., Donovan, N. J., Ward, A., Schultz, A., Lorius, N., Amariglio, R. E., Rentz, D. M., Johnson, K. A., Sperling, R. A., & Marshall, G. A. (2015) · The Journal of Neuropsychiatry and Clinical Neurosciences · doi:10.1176/appi.neuropsych.13060141 · Cited by 61 · cited 2×
“It has been shown to differentiate patients with probable AD dementia from CN elderly according to severity of apathy [32, 33], and has individuals at risk for AD due to MCI or advanced age (CN elderly) [22].”
Cited by
Neuropsychiatric signs and symptoms of Alzheimer's disease: New treatment paradigms
Lanctôt, K. L., Amatniek, J., Ancoli‐Israel, S., Arnold, S. E., Ballard, C., Cohen‐Mansfield, J., Ismail, Z., Lyketsos, C., Miller, D. S., Musiek, E., et al. (2017) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2017.07.001 · Cited by 395
“It is common in predementia states, increases in frequency as the disease progresses, and predicts conversion from normal cognition to MCI and MCI to dementia [72].”
BackgroundMethodDiagnosing and Treating Depression in Patients with Alzheimer’s Disease
Burke, A. D., Goldfarb, D., Bollam, P., & Khokher, S. (2019) · Neurology and Therapy · doi:10.1007/s40120-019-00148-5 · Cited by 115
Fathy, Y. Y., Hoogers, S. E., Berendse, H. W., van der Werf, Y. D., Visser, P. J., de Jong, F. J., & van de Berg, W. D. J. (2020) · Brain Imaging and Behavior · doi:10.1007/s11682-019-00099-3 · Cited by 82
Effects of dog-assisted therapy in adults with dementia: a systematic review and meta-analysis
Zafra-Tanaka, J. H., Pacheco-Barrios, K., Tellez, W. A., & Taype-Rondan, A. (2019) · BMC Psychiatry · doi:10.1186/s12888-018-2009-z · Cited by 64
Guzman-Martinez, L., Farías, G. A., Tapia, J. P., Sánchez, M. P., Fuentes, P., Gloger, S., & Maccioni, R. B. (2021) · Journal of Alzheimer's Disease · doi:10.3233/jad-201501 · Cited by 21
Metadata
- Authors
- Guercio, B. J., Donovan, N. J., Munro, C. E., Aghjayan, S. L., Wigman, S. E., Locascio, J. J., Amariglio, R. E., Rentz, D. M., Johnson, K. A., Sperling, R. A., & Marshall, G. A.
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2015-07-24
- Volume
- 47
- Issue
- 2
- Pages
- 421-432
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W1833856686
- Cited by
- 88
- References
- 37
- FWCI
- 4.10
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.